News... good news
Avivagen's U.S. Distributor Launches Oximunol™ Chewable Tablets for Dogs in the United States
For Immediate Release
OTTAWA, ONTARIO, September 25, 2012 – Avivagen Inc. (TSXV:VIV), a wellness company, is pleased to advise that its U.S. distributor has now commercially launched Oximunol™ Chewable Tablets for dogs through veterinarians in the United States. Avivagen’s CEO, David Hankinson, commented “We are very pleased that pet parents in the U.S. are now able to access Oximunol™ Chewable tablets to assist in optimizing the overall health and well-being of their dogs. It is also an important milestone in Avivagen’s history, which is important to all of our stakeholders. In early 2012, we announced the signing of a distribution agreement for the U.S. with a well-known and reputable animal health company, which was followed closely by accreditation received from the U.S. National Animal Supplement Council. We then received our first order from our U.S. distributor, which was delivered in August, 2012 and the product has now been commercially launched in the veterinary market. We are also pleased to confirm that we have received payment on our first order and look forward to fulfilling future orders for our distributor in the growing U.S. market.”
CEO David Hankinson also added, “We have been developing working relationships with companies in the international marketplace for the past while and this is a great first step in our international commercial efforts and brings our investors validation of demand for our Oximunol™ Chewables, while we seek distribution agreements in other territories and also to bring follow-on products to market.”
About Oximunol™ Chewables – “Optimized Health in a Chewable Tablet”
Oximunol™ is a scientifically formulated chewable tablet that contains Avivagen’s proprietary, patented active ingredient OxC-beta. OxC-beta is a highly concentrated version of oxidized derivatives of carotenoids that are found naturally and extensively in the plant world in minute amounts. It is currently available for dogs of all ages. Oximunol™ Chewables work with a dog’s immune system to optimize overall health and well-being.
About Avivagen
Avivagen, a wellness company, is developing and delivering products for animals and humans to assist in optimizing health and daily quality of life. Avivagen is advancing product candidates for the food animal market, companion animal market and various potential human applications. More information can be found at
www.avivagen.com.